1. Home
  2. AMTB vs CMPX Comparison

AMTB vs CMPX Comparison

Compare AMTB & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$22.51

Market Cap

922.1M

Sector

Finance

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.06

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
CMPX
Founded
1979
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
922.1M
927.5M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
AMTB
CMPX
Price
$22.51
$2.06
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$23.67
$14.57
AVG Volume (30 Days)
201.2K
12.1M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
1.57%
N/A
EPS Growth
386.36
N/A
EPS
0.44
N/A
Revenue
N/A
N/A
Revenue This Year
$8.29
N/A
Revenue Next Year
$7.67
$934.41
P/E Ratio
$50.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.62
$1.61
52 Week High
$24.38
$6.88

Technical Indicators

Market Signals
Indicator
AMTB
CMPX
Relative Strength Index (RSI) 44.58 34.36
Support Level $21.98 $1.61
Resistance Level $22.75 $3.54
Average True Range (ATR) 0.57 0.14
MACD -0.09 0.13
Stochastic Oscillator 49.13 78.75

Price Performance

Historical Comparison
AMTB
CMPX

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: